## Régis Bordet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9056171/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochemical Society Transactions, 2006, 34, 1341-1346.	3.4	263
2	Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes. Neurology, 2015, 85, 1408-1416.	1.1	165
3	Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Review of Neurotherapeutics, 2009, 9, 1413-1431.	2.8	120
4	Early MoCA predicts long-term cognitive and functional outcome and mortality after stroke. Neurology, 2018, 91, e1838-e1850.	1.1	119
5	Profile of and risk factors for poststroke cognitive impairment in diverse ethnoregional groups. Neurology, 2019, 93, e2257-e2271.	1.1	117
6	METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration: An initiative of the Joint Programme for Neurodegenerative Disease Research. Alzheimer's and Dementia, 2016, 12, 1235-1249.	0.8	82
7	Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?. PLoS ONE, 2016, 11, e0147947.	2.5	71
8	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	3.7	70
9	Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom?. BioMed Research International, 2014, 2014, 1-9.	1.9	64
10	Factors Associated with Poststroke Fatigue: A Systematic Review. Stroke Research and Treatment, 2015, 2015, 1-11.	0.8	64
11	Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a â€~European <scp>ADNI</scp> study'. Journal of Internal Medicine, 2016, 279, 576-591.	6.0	64
12	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research and Therapy, 2018, 10, 100.	6.2	64
13	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.8	62
14	Orolingual Angioedema During or After Thrombolysis for Cerebral Ischemia. Stroke, 2016, 47, 1825-1830.	2.0	54
15	Stroke-Induced Brain Parenchymal Injury Drives Blood–Brain Barrier Early Leakage Kinetics: A Combined <i>in Vivo</i> / <i>in Vitro</i> Study. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 95-107.	4.3	53
16	Post-mortem 7.0-tesla magnetic resonance study of cortical microinfarcts in neurodegenerative diseases and vascular dementia with neuropathological correlates. Journal of the Neurological Sciences, 2014, 346, 85-89.	0.6	46
17	The role of hemorrhage following spinal-cord injury. Brain Research, 2014, 1569, 9-18.	2.2	43
18	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Translational Psychiatry, 2020, 10, 403.	4.8	42

Régis Bordet

#	Article	IF	CITATIONS
19	Analysis of the association of MPO and MMP-9 with stroke severity and outcome. Neurology, 2020, 95, e97-e108.	1.1	42
20	Baclofen-Induced Manic Symptoms: Case Report and Systematic Review. Psychosomatics, 2014, 55, 326-332.	2.5	41
21	Biological and imaging predictors of cognitive impairment after stroke: a systematic review. Journal of Neurology, 2019, 266, 2593-2604.	3.6	38
22	Early treatment with atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischaemia. British Journal of Pharmacology, 2015, 172, 5188-5198.	5.4	31
23	Blood biomarkers in the early stage of cerebral ischemia. Revue Neurologique, 2016, 172, 198-219.	1.5	31
24	Antihypertensive agents in Alzheimer's disease: beyond vascular protection. Expert Review of Neurotherapeutics, 2020, 20, 175-187.	2.8	26
25	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. Magnetic Resonance Imaging, 2021, 76, 108-115.	1.8	24
26	Identification of a specific functional network altered in poststroke cognitive impairment. Neurology, 2018, 90, e1879-e1888.	1.1	23
27	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimer's and Dementia, 2021, 17, 1628-1640.	0.8	23
28	PPARs: A Potential Target for a Disease-Modifying Strategy in Stroke. Current Drug Targets, 2013, 14, 752-767.	2.1	23
29	Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus. Neuropharmacology, 2014, 85, 206-214.	4.1	21
30	The role of PPAR activation during the systemic response to brain injury. Journal of Neuroinflammation, 2015, 12, 99.	7.2	21
31	Thrombolytic therapy for stroke in patients with preexisting cognitive impairment. Neurology, 2014, 82, 2048-2054.	1.1	20
32	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience, 2022, 14, 840651.	3.4	20
33	Prediction of Long-term Cognitive Function After Minor Stroke Using Functional Connectivity. Neurology, 2021, 96, .	1.1	19
34	Long-term cognitive impairments following COVID-19: a possible impact of hypoxia. Journal of Neurology, 2022, 269, 3982-3989.	3.6	19
35	Hippocampal Deformations and Entorhinal Cortex Atrophy as an Anatomical Signature of Long-Term Cognitive Impairment: from the MCAO Rat Model to the Stroke Patient. Translational Stroke Research, 2018, 9, 294-305.	4.2	18
36	Biomarkers in the Prediction of Hemorrhagic Transformation in Acute Stroke: A Systematic Review and Meta-Analysis. Cerebrovascular Diseases, 2022, 51, 235-247.	1.7	18

RéGIS BORDET

#	Article	IF	CITATIONS
37	Cognitive Impairment After Sleep Deprivation Rescued by Transcranial Magnetic Stimulation Application in Octodon degus. Neurotoxicity Research, 2015, 28, 361-371.	2.7	15
38	Remote brain hemorrhage after IV thrombolysis. Neurology, 2020, 94, e961-e967.	1.1	14
39	Myeloneuropathy induced by recreational nitrous oxide use with variable exposure levels. European Journal of Neurology, 2022, 29, 2173-2180.	3.3	14
40	Influence of Medication on Fatigue Six Months after Stroke. Stroke Research and Treatment, 2016, 2016, 1-9.	0.8	13
41	Are the results of intravenous thrombolysis trials reproduced in clinical practice? Comparison of observed and expected outcomes with the stroke-thrombolytic predictive instrument (STPI). Revue Neurologique, 2017, 173, 381-387.	1.5	13
42	Neutrophils in tPA-induced hemorrhagic transformations: Main culprit, accomplice or innocent bystander?. , 2019, 194, 73-83.		13
43	Proportion of single-chain recombinant tissue plasminogen activator and outcome after stroke. Neurology, 2016, 87, 2416-2426.	1.1	12
44	Safety of oral anticoagulants on experimental brain microbleeding and cognition. Neuropharmacology, 2019, 155, 162-172.	4.1	12
45	Brain–liver axis: a new pathway for cognitive disorders related to hepatic fibrosis. European Journal of Neurology, 2020, 27, 2111-2112.	3.3	12
46	Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement. Revue Neurologique, 2020, 176, 100-112.	1.5	11
47	Transcranial magnetic stimulation and aging: Effects on spatial learning and memory after sleep deprivation in Octodon degus. Neurobiology of Learning and Memory, 2015, 125, 274-281.	1.9	10
48	Warning on increased serious health complications related to non-medical use of nitrous oxide. Therapie, 2021, 76, 478-479.	1.0	10
49	Drug interactions with dementiaâ€related pathophysiological pathways worsen or prevent dementia. British Journal of Pharmacology, 2019, 176, 3413-3434.	5.4	9
50	Role of cortical microbleeds in cognitive impairment: InÂvivo behavioral and imaging characterization of a novel murine model. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1015-1025.	4.3	9
51	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. Molecular Psychiatry, 2022, 27, 1990-1999.	7.9	9
52	Is the drug a scientific, social or political object?. Therapie, 2020, 75, 389-391.	1.0	8
53	Ongoing Electroencephalographic Activity Associated with Cortical Arousal in Transgenic PDAPP Mice (hAPP V717F). Current Alzheimer Research, 2018, 15, 259-272.	1.4	8
54	Sex Differences in Cognitive Impairment Induced by Cerebral Microhemorrhage. Translational Stroke Research, 2021, 12, 316-330.	4.2	8

Régis Bordet

#	Article	IF	CITATIONS
55	Which factors influence the resort to surrogate consent in stroke trials, and what are the patient outcomes in this context?. BMC Medical Ethics, 2015, 16, 26.	2.4	7
56	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	3.2	7
57	Early epileptic seizures in ischaemic stroke treated by mechanical thrombectomy: influence of rt-PA. Journal of Neurology, 2021, 268, 305-311.	3.6	5
58	Functional connectivity and cognitive changes after donepezil treatment in healthy participants. Psychopharmacology, 2021, 238, 3071-3082.	3.1	5
59	Lack of direct involvement of a diazepam long-term treatment in the occurrence of irreversible cognitive impairment: a pre-clinical approach. Translational Psychiatry, 2021, 11, 612.	4.8	5
60	Influence of cognitive impairment on the management of ischaemic stroke. Revue Neurologique, 2014, 170, 177-186.	1.5	4
61	A very early neurological improvement after intravenous thrombolysis for acute cerebral ischaemia does not necessarily predict a favourable outcome. Acta Neurologica Belgica, 2013, 113, 67-72.	1.1	3
62	Towards personalized pharmacology: Antipsychotics and schizophrenia. Therapie, 2021, 76, 137-147.	1.0	3
63	Beneficial effects of atorvastatin on sexâ€specific cognitive impairment induced by a cerebral microhaemorrhage in mice. British Journal of Pharmacology, 2021, 178, 1705-1721.	5.4	3
64	Medical Pharmacology: From Review to Planning. Therapie, 2006, 61, 457-461.	1.0	2
65	Contributions of animal models of cognitive disorders to neuropsychopharmacology. Therapie, 2021, 76, 87-99.	1.0	2
66	Texture Features of Magnetic Resonance Images Predict Poststroke Cognitive Impairment: Validation in a Multicenter Study. Stroke, 2022, 53, 3446-3454.	2.0	2
67	Stroke prevention: Management of modifiable vascular risk factors. Journal of Neurology, 2003, 250, 1125-1126.	3.6	1
68	Age and diet modify acute microhemorrhage outcome in the mouse brain. Neurobiology of Aging, 2021, 98, 99-107.	3.1	1
69	Effects of acute ethanol and/or diazepam exposure on immediate and delayed hippocampal metabolite levels in rats anesthetized with isoflurane. Fundamental and Clinical Pharmacology, 2022, 36, 687-698.	1.9	1
70	Ischémie cérébraleÂ: la fin de la fatalitéÂ?. Bulletin De L'Academie Nationale De Medecine, 2019, 203, 144-153.	0.0	0